GlassScriptPhysician profile
Rehan Ajmal Sarmad
NPI 1417398033
$4,487.32
in general payments reported to CMS, 2019-2025
52 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.00 · 2020: $114 · 2021: $112 · 2022: $218 · 2023: $959 · 2024: $1,429 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Education: $45.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.91 |
| Education | $45.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $536.73 | 2021-2025 | |
| Celgene Corporation | $320.27 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $309.37 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $293.54 | 2023-2025 | Libtayo, Lynozyfic |
| Beigene USA, INC. | $185.96 | 2022-2025 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $142.05 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Janssen Biotech, INC. | $140.46 | 2023-2025 | Darzalex, Talvey, Balversa |
| Deciphera Pharmaceuticals INC. | $132.04 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Astrazeneca Pharmaceuticals LP | $130.77 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Pharmaessentia USA Corporation | $128.65 | 2023-2025 | Besremi |
| Amgen INC. | $126.75 | 2019-2022 | |
| Abbvie INC. | $124.24 | 2022-2025 | Venclexta |
| Astellas Pharma US INC | $117.21 | 2023-2025 | Xospata, Padcev, Vyloy |
| Novocure INC. | $109.06 | 2020-2025 | Optune Lua (Novottf-200t) |
| Genmab U.S., INC. | $102.48 | 2024-2025 | Epkinly |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $99.12 | 2023-2024 | |
| Exelixis INC. | $97.55 | 2024-2025 | Cabometyx |
| Beone Medicines USA, INC. | $95.60 | 2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $94.28 | 2023-2025 | Orserdu |
| Merck Sharp & Dohme LLC | $89.92 | 2021-2025 | Reblozyl, Welireg, Keytruda |
| Daiichi Sankyo INC. | $80.51 | 2024-2025 | Enhertu |
| Incyte Corporation | $76.42 | 2023-2024 | Monjuvi, Jakafi, Pemazyre |
| Array Biopharma INC | $68.13 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $59.33 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $59.30 | 2024 | Bracanalysis Cdx |
| Genentech USA, INC. | $58.70 | 2024-2025 | Phesgo, Itovebi, Tecentriq |
| Emd Serono, INC. | $58.50 | 2023-2025 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $57.84 | 2023 | Imbruvica |
| Seagen INC. | $52.16 | 2023 | Tukysa, Padcev |
| Tersera Therapeutics LLC | $50.33 | 2025 | Quzyttir |
| Kite Pharma, INC. | $45.27 | 2021-2025 | Yescarta |
| Glaxosmithkline, LLC. | $44.04 | 2023-2025 | Ojjaara, Blenrep, Shingrix |
| Eisai INC. | $41.05 | 2023-2025 | |
| Acrotech Biopharma INC. | $36.90 | 2022-2025 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $32.40 | 2023-2024 | Somatuline Depot, Onivyde |
| E.R. Squibb & Sons, L.L.C. | $28.05 | 2022 | |
| Csl Behring | $25.14 | 2025 | Privigen |
| Dendreon Pharmaceuticals LLC | $23.41 | 2025 | Provenge |
| Sun Pharmaceutical Industries INC. | $22.29 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.33 | 2025 | |
| Kyowa Kirin, INC. | $17.62 | 2025 | |
| Aveo Pharmaceuticals, INC. | $17.28 | 2023 | Fotivda |
| Alexion Pharmaceuticals, INC. | $16.87 | 2023 | Ultomiris |
| Adc Therapeutics America, INC. | $16.86 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.19 | 2022 | |
| Puma Biotechnology, INC. | $15.25 | 2023 | Nerlynx |
| Karyopharm Therapeutics INC. | $13.93 | 2023 | Xpovio |
| Sumitomo Pharma America, INC. | $13.51 | 2024 | Orgovyx |
| Lilly USA, LLC | $13.38 | 2024 | Verzenio, Jaypirca, Retevmo |
| Morphosys, US INC. | $11.54 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Rigel Pharmaceuticals, INC. | $9.24 | 2024 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Ajmal Sarmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.